文献速递慢性肾脏病遗传性与小管间质肾病

仅伴结晶尿的高尿酸血症驱动CKD进展,无症状高尿酸血症无此作用

Only Hyperuricemia with Crystalluria, but not Asymptomatic Hyperuricemia, Drives Progression of Chronic Kidney Disease.
PubMed 文献 · J Am Soc Nephrol · 2020-09-16

该研究利用新型高尿酸血症伴慢性尿酸结晶肾病小鼠模型,发现无症状高尿酸血症本身不导致CKD或驱动现有CKD进展;仅当尿酸在肾脏结晶(结晶尿)时,才引起肾小管阻塞、炎症和间质纤维化,且尿酸结晶肉芽肿及M1样巨噬细胞在晚期形成并促进CKD进展。抑制M1样巨噬细胞可减轻肉芽肿性肾炎和GFR下降,而抑制JAK/STAT通路无肾脏保护作用。

要点

  • 无症状高尿酸血症不驱动CKD进展,除非尿酸在肾脏结晶。
  • 尿酸结晶尿导致肾小管阻塞、炎症和间质纤维化。
  • 靶向促炎M1样巨噬细胞可减轻肉芽肿性间质性肾炎。

核心结论

  • 无症状高尿酸血症不影响CKD进展,除非尿酸在肾脏结晶。
  • 尿酸结晶肉芽肿在慢性尿酸结晶肾病晚期形成,并通过M1样巨噬细胞相关间质炎症和纤维化促进CKD进展。
  • 靶向促炎巨噬细胞而非JAK/STAT信号可减轻肉芽肿性间质性肾炎。

研究设计与样本

  • 采用MALDI-FTICR质谱、免疫组化、3D共聚焦显微镜和流式细胞术表征新型高尿酸血症伴慢性尿酸结晶肾病及肉芽肿性肾炎小鼠模型。
  • 通过干预性研究探讨结晶诱导炎症和巨噬细胞在进展性CKD病理中的作用。

主要发现

  • 无症状高尿酸血症 alone 不导致CKD,也不驱动马兜铃酸I诱导的CKD进展。
  • 仅因尿液酸化导致尿酸结晶尿的高尿酸血症引起肾小管阻塞、炎症和间质纤维化。
  • 尿酸结晶肉芽肿被促炎M1样巨噬细胞包围,在慢性尿酸结晶肾病晚期形成,并促进已有CKD进展。
  • 用腺苷抑制M1样巨噬细胞可减轻肉芽肿性肾炎和GFR的进行性下降。
  • 用托法替尼抑制JAK/STAT炎症通路无肾脏保护作用。

临床怎么用

  • 临床应关注高尿酸血症患者是否出现尿酸结晶尿,而非仅依据血尿酸水平评估CKD进展风险。
  • 针对促炎M1样巨噬细胞的策略可能成为尿酸结晶相关CKD的治疗方向。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The roles of asymptomatic hyperuricemia or uric acid (UA) crystals in CKD progression are unknown. Hypotheses to explain links between UA deposition and progression of CKD include that (1) asymptomatic hyperuricemia does not promote CKD progression unless UA crystallizes in the kidney; (2) UA crystal granulomas may form due to pre-existing CKD; and (3) proinflammatory granuloma-related M1-like macrophages may drive UA crystal-induced CKD progression. METHODS: MALDI-FTICR mass spectrometry, immunohistochemistry, 3D confocal microscopy, and flow cytometry were used to characterize a novel mouse model of hyperuricemia and chronic UA crystal nephropathy with granulomatous nephritis. Interventional studies probed the role of crystal-induced inflammation and macrophages in the pathology of progressive CKD. RESULTS: Asymptomatic hyperuricemia alone did not cause CKD or drive the progression of aristolochic acid I-induced CKD. Only hyperuricemia with UA crystalluria due to urinary acidification caused tubular obstruction, inflammation, and interstitial fibrosis. UA crystal granulomas surrounded by proinflammatory M1-like macrophages developed late in this process of chronic UA crystal nephropathy and contributed to the progression of pre-existing CKD. Suppressing M1-like macrophages with adenosine attenuated granulomatous nephritis and the progressive decline in GFR. In contrast, inhibiting the JAK/STAT inflammatory pathway with tofacitinib was not renoprotective. CONCLUSIONS: Asymptomatic hyperuricemia does not affect CKD progression unless UA crystallizes in the kidney. UA crystal granulomas develop late in chronic UA crystal nephropathy and contribute to CKD progression because UA crystals trigger M1-like macrophage-related interstitial inflammation and fibrosis. Targeting proinflammatory macrophages, but not JAK/STAT signaling, can attenuate granulomatous interstitial nephritis.

来源:J Am Soc Nephrol,查看原文。版权归原作者所有。

引用

  1. Sellmayr M, Hernandez Petzsche MR, Ma Q, et al. Only Hyperuricemia with Crystalluria, but not Asymptomatic Hyperuricemia, Drives Progression of Chronic Kidney Disease. J Am Soc Nephrol. 2020. PMID: 32938648. doi:10.1681/ASN.2020040523

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。